Physician profile
Jennifer Cunningham
NPI 1265839864
$1,992.17
in general payments reported to CMS, 2019-2025
27 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $561 · 2022: $660 · 2023: $309 · 2024: $341 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $770.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $427.95 | 2021-2024 | Xarelto |
| Daiichi Sankyo INC. | $197.54 | 2021-2023 | Injectafer |
| Novo Nordisk INC | $189.48 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Mylan Specialty L.P. | $138.57 | 2022-2024 | Yupelri |
| Lilly USA, LLC | $125.76 | 2022-2024 | Mounjaro, Amyvid |
| Avanir Pharmaceuticals, INC. | $120.92 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $97.75 | 2021-2023 | Eliquis, Camzyos |
| Pfizer INC. | $96.67 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $77.36 | 2021-2025 | Brilinta, Airsupra |
| Kowa Pharmaceuticals America, INC. | $56.09 | 2021 | |
| Novartis Pharmaceuticals Corporation | $51.31 | 2021-2022 | |
| Abbvie INC. | $47.85 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.50 | 2022 | |
| Almatica Pharma LLC | $41.22 | 2021-2022 | |
| Shield Therapeutics INC | $39.32 | 2023 | Accrufer |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $34.11 | 2023-2024 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.07 | 2024 | |
| Amarin Pharma, INC. | $25.33 | 2021-2022 | |
| Viatris Specialty LLC | $21.68 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $20.91 | 2022 | |
| Exact Sciences Corporation | $18.27 | 2025 | Cologuard Collection Kit |
| Ultragenyx Pharmaceutical INC. | $17.00 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.48 | 2023 | Voquezna |
| Opko Pharmaceuticals, LLC | $15.40 | 2022 | |
| Glaxosmithkline, LLC. | $14.51 | 2024 | Trelegy Ellipta, Arexvy |
| Sunovion Pharmaceuticals INC. | $13.24 | 2022 | |
| Merck Sharp & Dohme LLC | $11.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.